Redhill Biopharma (NASDAQ:RDHL – Get Free Report) and Nutriband (NASDAQ:NTRB – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.
Analyst Recommendations
This is a breakdown of current recommendations for Redhill Biopharma and Nutriband, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Redhill Biopharma | 1 | 0 | 0 | 0 | 1.00 |
| Nutriband | 1 | 1 | 0 | 0 | 1.50 |
Valuation & Earnings
This table compares Redhill Biopharma and Nutriband”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Redhill Biopharma | $286,000.00 | 17.42 | -$430,000.00 | $1,046.75 | 0.00 |
| Nutriband | $2.04 million | 21.61 | -$8.23 million | ($2.60) | -1.39 |
Redhill Biopharma has higher earnings, but lower revenue than Nutriband. Nutriband is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
7.2% of Redhill Biopharma shares are held by institutional investors. Comparatively, 19.7% of Nutriband shares are held by institutional investors. 6.8% of Redhill Biopharma shares are held by company insiders. Comparatively, 52.2% of Nutriband shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Volatility & Risk
Redhill Biopharma has a beta of 5.05, indicating that its share price is 405% more volatile than the S&P 500. Comparatively, Nutriband has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500.
Profitability
This table compares Redhill Biopharma and Nutriband’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Redhill Biopharma | N/A | N/A | N/A |
| Nutriband | -403.98% | -118.33% | -101.92% |
Summary
Redhill Biopharma beats Nutriband on 7 of the 12 factors compared between the two stocks.
About Redhill Biopharma
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
About Nutriband
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Receive News & Ratings for Redhill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
